Jean-François Nicolas Selected Research

Haptens

1/2014	Human T cell priming assay: depletion of peripheral blood lymphocytes in CD25(+) cells improves the in vitro detection of weak allergen-specific T cells.
4/2013	Invariant NKT cells suppress CD8(+) T-cell-mediated allergic contact dermatitis independently of regulatory CD4(+) T cells.
1/2012	Natural killer cells and T cells induce different types of skin reactions during recall responses to haptens.
7/2009	Allergic and irritant contact dermatitis.
5/2009	Skin exposure to weak and moderate contact allergens induces IFNgamma production by lymph node cells of CD4+ T-cell-depleted mice.
4/2006	CD8+ T cells are effector cells of contact dermatitis to common skin allergens in mice.
2/2006	[Epidemiology and pathophysiology of eczemas].
2/2006	[Allergic contact dermatitis: how to re-induce tolerance?].
2/2006	Pathophysiology of urticaria.
9/2004	CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-François Nicolas Research Topics

Disease

22	Hypersensitivity (Allergy) 10/2022 - 05/2004
14	Contact Dermatitis (Eczema, Contact) 12/2021 - 01/2002
12	Inflammation (Inflammations) 07/2022 - 01/2002
12	Allergic Contact Dermatitis 02/2019 - 05/2004
8	Atopic Dermatitis (Atopic Eczema) 02/2019 - 02/2006
6	Skin Diseases (Skin Disease) 01/2020 - 07/2003
5	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2020 - 01/2004
5	Eczema 01/2019 - 02/2006
5	Urticaria (Hives) 04/2013 - 09/2004
4	Chronic Urticaria 01/2018 - 09/2004
3	Neoplasms (Cancer) 10/2022 - 08/2010
3	Immediate Hypersensitivity 10/2022 - 02/2006
3	Dermatitis 12/2021 - 03/2006
3	Exanthema (Rash) 10/2015 - 09/2015
3	Angioedema 01/2015 - 04/2013
3	Human Influenza (Influenza) 01/2014 - 10/2008
2	Food Hypersensitivity (Food Allergy) 11/2022 - 01/2011
2	Drug Hypersensitivity (Drug Allergy) 10/2022 - 10/2015
2	Drug Hypersensitivity Syndrome 10/2015 - 12/2012
2	Measles 09/2007 - 08/2007
1	Blister (Bulla) 01/2021
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Systemic Scleroderma (Systemic Sclerosis) 01/2020
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020
1	Aseptic Meningitis 07/2018
1	Anaphylaxis (Anaphylactic Shock) 01/2018
1	Eosinophilia 10/2015
1	Injection Site Reaction 09/2015
1	Porokeratosis (Palmoplantar Porokeratosis) 03/2014
1	Optic Neuritis (Retrobulbar Neuritis) 12/2012
1	Latent Tuberculosis 09/2012
1	Atrophy 06/2011
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 06/2011
1	Erythema Multiforme 05/2011
1	Pathologic Complete Response 05/2011
1	Angiokeratoma 11/2008
1	Rabies (Hydrophobia) 10/2008

Drug/Important Bio-Agent (IBA)

19	AllergensIBA 07/2022 - 07/2003
13	HaptensIBA 01/2014 - 03/2002
8	Pharmaceutical PreparationsIBA 10/2022 - 12/2012
7	AntigensIBA 01/2020 - 01/2002
5	DinitrofluorobenzeneIBA 01/2019 - 01/2002
4	Irritants (Vesicants)IBA 07/2022 - 09/2004
4	Proteins (Proteins, Gene)FDA Link 04/2018 - 09/2004
4	Methotrexate (Mexate)FDA LinkGeneric 03/2018 - 11/2003
3	Histamine Antagonists (Antihistamines)IBA 01/2018 - 04/2013
3	VaccinesIBA 01/2014 - 10/2008
3	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2011 - 09/2004
3	Immunoglobulin E (IgE)IBA 05/2011 - 02/2006
3	CytokinesIBA 02/2006 - 01/2004
2	Biomarkers (Surrogate Marker)IBA 07/2022 - 12/2021
2	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 02/2006
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2015 - 04/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2012 - 09/2012
2	XenobioticsIBA 07/2009 - 02/2006
2	CosmeticsIBA 01/2009 - 12/2007
2	AntibodiesIBA 11/2007 - 02/2006
2	Histamine (Histamine Dihydrochloride)FDA Link 02/2006 - 09/2004
1	OvalbuminIBA 11/2022
1	Antineoplastic Agents (Antineoplastics)IBA 10/2022
1	LanolinIBA 07/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 04/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	brodalumabIBA 12/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	Ficusin (Psoralen)IBA 01/2020
1	2-methyl-4-isothiazolin-3-oneIBA 02/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	MucinsIBA 01/2019
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2018
1	Polysorbates (PSML)FDA Link 01/2018
1	Omalizumab (Xolair)FDA Link 01/2018
1	Excipients (Suspending Agents)IBA 01/2018
1	Thymic Stromal LymphopoietinIBA 01/2017
1	beta Lactam AntibioticsIBA 10/2015
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 09/2015
1	Biological ProductsIBA 05/2014
1	BradykininIBA 05/2014
1	Interleukin-13IBA 04/2013
1	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 04/2013
1	Interleukin-4 (Interleukin 4)IBA 04/2013
1	Amikacin (A.M.K)FDA LinkGeneric 12/2012
1	Tuberculin (PPD)IBA 09/2012
1	Hair DyesIBA 07/2012
1	Ethanol (Ethyl Alcohol)IBA 06/2011
1	SuspensionsIBA 06/2011
1	SteroidsIBA 05/2011
1	Volatile Oils (Essential Oils)IBA 05/2011
1	Histamine Receptors (Histamine Receptor)IBA 04/2011
1	Lactoglobulins (beta-Lactoglobulin)FDA Link 01/2011
1	Local AnestheticsIBA 07/2009
1	AmidesIBA 07/2009
1	Etanercept (Enbrel)FDA Link 11/2008

Therapy/Procedure

2	Immunotherapy 11/2022 - 02/2006
1	Photopheresis 01/2020
1	Contraindications 01/2020
1	Drug Therapy (Chemotherapy) 03/2014
1	Premedication 04/2013
1	Intradermal Injections 06/2011